With robot servers, the metaverse, and automation, it is clear that we’ve officially entered the era of advanced technology. This is also true for the life sciences industry.
With robot servers, the metaverse, and automation, it is clear that we’ve officially entered the era of advanced technology. This is also true for the life sciences industry.
A group of researchers from the Institute of Health Carlos III (ISCIII) in Spain, presented a poster at the annual meeting for the International Society of Extracellular Vesi
Currently, there is limited technology available for accurately predicting high-risk cancer biochemical recurrence (BCR).
Cell therapy using cardiosphere-derived cells (CDCs) is an increasingly promising treatment for acute and congenital heart muscle injuries, including myocardial infarction (MI).
The National Institute of Health estimates that approximately 6 in 100 000 individuals develop brain or central nervous system-related cancers each year1. Current approaches in the diagnosis of brain cancer include CT scans, MRI and tissue biopsy.
RNA isolation and quantification of miRNAs are gaining significance as promising methods in cancer biomarker discovery.
Disease is defined as a state of disorder that lays the groundwork for conditions of ill health. Even the most complex disease begins with cellular imbalance, and scientists are looking to discover biomarkers that can detect the earliest signs of pathogenesis.